- 1 Outcomes of possible and probable rheumatic fever: a cohort study
- 2 using northern Australian register data, 2013-2019
- 3
- 4 Laura Goddard^{1,2}, Mirjam Kaestli^{1,3}, Enes Makalic², Anna P. Ralph^{1*}
- 5
- 6 1. Global and Tropical Health Division, Menzies School of Health Research, Charles
- 7 Darwin University, Darwin, Northern Territory, Australia
- 8 2. School of Global and Population Health, University of Melbourne, Melbourne, Victoria,
- 9 Australia
- 10 3. Research Institute for the Environment and Livelihoods, Charles Darwin University,
- 11 Darwin, Northern Territory, Australia
- 12
- 13 *Corresponding author
- 14 E-mail: anna.ralph@menzies.edu.au

15 Abstract

Background: Outcomes after acute rheumatic fever (ARF) diagnosis are variable, ranging from recovery to development of severe rheumatic heart disease (RHD). There is no diagnostic test. Evaluation using the Australian clinical diagnostic criteria can result in a diagnosis of 'definite', 'probable' or 'possible' ARF. The 'possible' category was introduced in 2013 in Australia's Northern Territory (NT). Our aim was to compare longitudinal outcomes after a diagnosis of definite, probable or possible ARF.

22 Methods: We extracted data from the NT RHD register for Indigenous Australians with an 23 initial diagnosis of ARF during the 5.5-year study period (01/01/2013 – 30/06/2019). 24 Descriptive statistics were used to describe the demographic and clinical characteristics at 25 initial ARF diagnosis. Kaplan-Meier curves were used to assess the probability of survival free 26 of disease progression and the cumulative incidence risk at each year since initial diagnosis 27 was calculated. Cox proportional hazards regression was used to determine whether time to 28 disease progression differed according to ARF diagnosis and whether progression was 29 associated with specific predictors at diagnosis. A multinomial logistic regression model was 30 performed to assess whether ARF diagnosis was associated with RHD outcome and to assess 31 associations between ARF diagnosis and clinical manifestations. A generalised linear mixed 32 model (GLMM) was developed to assess any differences in the long-term antibiotic adherence 33 between ARF diagnosis categories and to examine longitudinal trends in adherence.

Results: There were 913 initial ARF cases, 732 with normal baseline echocardiography. Of these, 92 (13%) experienced disease progression: definite ARF 61/348 (18%); probable ARF 20/181 (11%); possible ARF 11/203 (5%). The proportion of ARF diagnoses that were uncertain (i.e. possible or probable) increased over time, from 22/78 (28%) in 2013 to 98/193 (51%) in 2018. Cumulative incidence risk of any disease progression at 5.5 years was 33.6 (23.6–46.2) for definite ARF, 13.5 (8.8–20.6) for probable and 11.4% (95% CI 6.0–21.3) for possible ARF. The probability of disease-free survival was lowest for definite ARF and highest

41 for possible ARF (p=0.004). Cox proportional hazards regression indicated that disease 42 progression was 2.19 times more likely in those with definite ARF than those with possible ARF (p=0.026). Progression to RHD was reported in 37/348 (11%) definite ARF, 10/181 (6%) 43 probable ARF, and 5/203 (2%) possible ARF. The multinomial logistic regression model 44 45 demonstrated a significantly higher risk of progression from no RHD to RHD if the initial diagnosis was definite compared to possible ARF (p<0.001 for both mild and moderate-severe 46 47 RHD outcomes). The GLMM estimated that patients with definite ARF had a significantly 48 higher adherence to antibiotic prophylaxis compared with probable ARF (p=0.024). 49 Conclusion: These data indicate that the ARF diagnostic categories are being applied

appropriately, are capturing more uncertain cases over time, provide a useful way to stratify
 risk and guide prognosis, and can help inform practice. Possible ARF is not entirely benign;
 some cases progress to RHD.

53 Introduction

54 In Australia, high burdens of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) 55 occur among Aboriginal and Torres Strait Islander peoples, particularly across northern and 56 central Australia.(1) There is no diagnostic test for ARF. This impairs case detection and 57 opportunities for early intervention with antibiotic secondary prophylaxis.(2) The Jones Criteria 58 are syndromic criteria to diagnose ARF, dividing the clinical features into major and minor 59 manifestations based on their prevalence and specificity.(3) The Jones Criteria have been 60 regularly revised in response to evolving clinical knowledge and epidemiology, to reduce 61 overdiagnosis in high-resource settings where ARF has become uncommon.(4-6) As a result, 62 they became less sensitive for detection of cases in high-incidence populations. Different 63 considerations were therefore added for high-risk groups (3, 5, 6), but to further avoid missed diagnoses in high-prevalence Aboriginal communities in Australia, additional diagnostic 64 65 categories of 'possible' and 'probable' ARF were proposed.(7) This proposal was adopted and 66 since 2013, diagnoses in Australia have been grouped as: possible ARF, probable ARF, 67 definite ARF, and RHD. The distinction between probable and possible is subjective and requires thoughtful clinical decision making. These categories were further clarified in the 68 69 revised 2020 Australian Guidelines (Box 1).(3) This is in contrast to international guidelines 70 that only articulate two categories: definite and probable ARF.(6)

71

72 Box 1: Acute rheumatic fever diagnostic categories, 2020 Australian Guidelines (6)

Definite ARF: acute presentation which fulfils the 2015 Revised Jones diagnostic criteria for ARF.

Probable ARF: acute presentation which does not fulfil Jones diagnostic criteria for ARF, missing one major or one minor criterion or lacking evidence of preceding streptococcal infection, but ARF is still considered the most likely diagnosis.

Possible ARF: acute presentation which does not fulfil Jones diagnostic criteria for ARF, missing one major or one minor criterion or lacking evidence of preceding streptococcal infection, and ARF is considered uncertain but cannot be ruled out.

73

Previous research has described progression from ARF to RHD and other outcomes such as morbidity and mortality rates.(8, 9) In Australia's Northern Territory (NT), the risk of progression from definite ARF to RHD is high, with a cumulative incidence of progression of 27.1% at 1 year after diagnosis, 44.0% at 5 years and 51.9% at 10 years.(9) Adherence to penicillin to prevent rheumatic fever recurrences reduces risk, with a dose-dependent effect.(10) Previous studies routinely exclude possible ARF and often also exclude probable ARF cases, so long-term outcomes of these diagnoses remain unknown.

81

To provide patients with better prognostic information, determine whether clinicians appear to be applying diagnostic categories appropriately, and reflect on whether current management guidelines (3) are appropriate, the aim of this study is to describe patient outcomes after a diagnosis of possible or probable (collectively, 'uncertain') ARF, compared with definite ARF. Further aims are to determine whether uncertain diagnoses differ from definite ARF in demographic or clinical characteristics, severity of RHD if there is progression to RHD, and penicillin adherence over time.

89

90 Methods

91 Study design and data sources

We used a retrospective cohort design and Cox proportional hazards regression to analyse
the probability of disease progression after an initial diagnosis of ARF. Sub-analyses on initial
ARF diagnoses with RHD outcome and adherence to penicillin adherence were conducted

95 using multinomial logistic regression and generalised linear mixed-effects models (GLMM) 96 respectively. Data were extracted from the NT RHD Register (the Register) for a 5.5-year 97 period (01/01/2013 – 30/06/2019). The Register was established in 1997 as a tool to support 98 and coordinate care. Since then, all notified cases of ARF (including recurrent episodes) and 99 RHD in the NT have been recorded, capturing approximately 3,500 individuals at the time of 100 data extraction. The Register includes data on patient demographics, clinical features of ARF 101 and RHD, medical appointments and secondary penicillin prophylaxis, which is generally 102 required long-term after probable and definite ARF, and short term (12 months) after possible 103 ARF. Mortality data from the NT Births, Deaths and Marriages database are reviewed monthly 104 and integrated with the Register.

105

106 Study population and sample

107 The study population was defined as Indigenous Australians residing in the NT, which is 108 approximately 74,546 or 30% of the total NT population.(11, 12) The Register contained 109 information on 1,140 individuals with 1,567 diagnoses during the study period. Indigenous 110 Australians residing in the NT who were registered with an initial diagnosis of possible, 111 probable or definite ARF on the Register during the study period were included. Exclusions 112 comprised non-Indigenous people (11; 1%); cases whose first documented ARF episode was 113 labelled a recurrence (216; 19%); and concurrent ARF and RHD diagnoses (180; 16%). Those 114 whose first documented episode was labelled a recurrence were assumed to have had a 115 previous diagnosis of ARF before the study period began or in a different jurisdiction. One 116 case whose initial diagnosis date was on the final day of the study period was excluded from 117 the disease progression analyses due to a survival time of zero. Concurrent ARF and RHD 118 diagnoses (180 cases) were similarly excluded from disease progression analyses since they 119 had a disease-free survival time of zero. These cases represent severe ARF which has 120 already progressed to RHD at the time of first echocardiogram, or ARF occurring in someone

with previously unrecognised latent RHD, or documentation of rheumatic carditis in the register as RHD (since distinguishing rheumatic carditis from established RHD is not always possible, and misclassification may occur during clinical reporting or data entry). The exclusions mean that the most severe form of ARF (definite ARF with carditis classified as RHD, or carditis complicating RHD), were excluded from the Cox regressions but were still accounted for in the multinomial model. The final sample size for the Cox regression was 732 cases and 913 cases for the multinomial model.

128

129 Outcomes

The main outcome of interest was time to disease progression. Disease progression was defined as progression from possible to probable ARF, definite ARF or RHD; probable to definite ARF or RHD; or definite ARF to definite ARF recurrence or RHD at any time during the study period (Table 1). Individuals could progress and regress more than once during the study period, however only the first progression was counted.

135

136 Table 1. Definitions of disease progression

| Initial ARF diagnosis | Subsequent diagnosis |
|-----------------------|-----------------------------------|
| ARF possible | ARF probable, ARF definite or RHD |
| ARF probable | ARF definite or RHD |
| ARF definite | ARF definite recurrence or RHD |
| | |

137

We also calculated the proportion of those without baseline carditis who progressed to RHD
and the risk to develop mild or moderate to severe RHD compared to no RHD based on initial
ARF diagnosis.

141

Adherence to secondary prophylaxis with benzathine benzylpenicillin (BPG) was calculated as the percentage of received doses / prescribed doses x100. BPG is usually required once every 28 days for ARF secondary prophylaxis, i.e. 13 doses per year, but may be prescribed every 21 days, i.e. 17 doses per year, in more severe or breakthrough cases. The number of

prescribed doses was estimated by dividing the number of days that BPG was prescribed (last dose date minus first dose date) divided by 21 or 28 for 3-weekly and 4-weekly BPG respectively. Adherence calculations were restricted to cases that had been prescribed at least 6 doses of BPG (equivalent to 168 days for a 4-weekly regimen). Adherence was considered good if \geq 80% of injections were received.

151

152 Predictors

153 Predictors used in the analyses included initial ARF diagnosis, sex, age group, clinical 154 manifestations, and adherence to secondary prophylaxis. Initial ARF diagnosis was defined 155 as the first diagnosis of possible, probable or definite ARF on the Register. Sex was classified 156 as per the NT RHD register (male, female, unknown). Age at initial diagnosis was grouped as 157 0-4, 5-14, 15-24, ≥25 years; these have different risk profiles for ARF and RHD.(3) Clinical 158 manifestations were grouped as major manifestations (carditis; arthritis or 'joint'; Sydenham's 159 Chorea; and subcutaneous nodules and erythema marginatum or 'skin'), minor manifestations 160 (fever; elevated ESR or CRP; prolonged P-R interval on ECG), and evidence of Group A 161 streptococcal infection (elevated serological titre or cultured from throat swab) as per the RHDAustralia Clinical Guidelines.(3) The definition of adherence is described in the outcomes 162 163 section. Individuals who had missing data for adherence are excluded from analyses as these 164 data are unlikely to be missing at random and keeping these individuals in the analysis may 165 therefore introduce bias.

166

167 Statistical analysis

Descriptive statistics were used to describe the demographic and clinical characteristics at initial ARF diagnosis (possible, probable, definite). Kaplan-Meier curves and log rank test were used to assess the probability of survival free of disease progression and the cumulative incidence risk at each year since initial diagnosis was calculated. Cox proportional hazards

172 regression was used to determine whether time to disease progression differed according to 173 ARF diagnosis category (definite, probable, possible), and whether it was predicted by age 174 group at diagnosis, sex, adherence to secondary prophylaxis or clinical manifestations (joint 175 manifestation-only and joint manifestation with carditis and/or chorea) at diagnosis. Hazard 176 ratios, 95% CI and p-values are reported.

177

178 A multinomial logistic regression model was performed to assess whether ARF diagnosis type 179 (definite, probable, possible) was associated with RHD outcome (no RHD, mild RHD 180 moderate-severe RHD). Moderate and severe RHD were combined to increase observations 181 per group level. Predictors included age group, sex, drug adherence and clinical 182 manifestations (carditis-only or joint manifestations-only. Chorea-only was excluded due to 183 the small number of observations). Multinomial logistic regression was also used to assess 184 associations between clinical manifestations (Jones major criteria) and ARF diagnosis. 185 Relative risk ratios, 95% confidence intervals (CI) and p-values were calculated for clinical 186 manifestations, age at diagnosis and sex, using definite ARF as the reference group.

187

A GLMM (beta regression family) was developed to assess any differences in the long-term antibiotic adherence between ARF diagnosis categories and examine longitudinal trends in adherence (glmmTMB package in R). This took into account the number of years receiving BPG prophylaxis and a random intercept for patient identification. Model residuals were checked for lack of patterns across fitted values and predictors (DHARMa package) and no temporal autocorrelation.

194

Data were analysed using STATA version 15.1 (STATA Corp, College Station, TX), R (v4.1.3;
R Project for Statistical Computing, Vienna, Austria) and Microsoft Excel (2016).

197

198 Ethics approval

199 Study approval was granted by the Human Research Ethics Committee of the Northern 200 Territory Department of Health and Menzies School of Health Research (2019-3482). This 201 approval was registered with the University of Melbourne's Medicine and Dentistry Human 202 Ethics Sub-Committee (1955194). Access to register data was approved by the data 203 custodian, Top End Health Service, NT Department of Health.

204

205 **Results**

206 Demographic and clinical characteristics

207 During the study period there were 913 initial diagnoses of ARF among eligible register 208 participants: 509 (56%) definite, 196 (21%) probable and 208 (23%) possible ARF. All ARF 209 types were more common among females than males and in those aged 5-14 years compared

210 with other age groups (**Error! Reference source not found.**).

211

Table 2. Characteristics at initial acute rheumatic fever diagnosis among Indigenous

213 Australians, NT, 2013-2019

| Characteristic | ARF | | | | | Тс | tal | |
|-------------------|----------|-------|------|----------|-----|----------|-----|-------|
| | Possible | | Prob | Probable | | Definite | | |
| | n | (%) | n | (%) | n | (%) | n | (%) |
| Cases | 208 | (100) | 196 | (100) | 509 | (100) | 913 | (100) |
| Sex | | | | | | | | |
| Male | 97 | (47) | 87 | (44) | 243 | (48) | 427 | (47) |
| Female | 111 | (53) | 109 | (56) | 266 | (52) | 486 | (53) |
| Age group (years) | | | | | | | | |
| 0-4 | 25 | (12) | 11 | (6) | 27 | (5) | 63 | (7) |
| 5-14 | 113 | (54) | 92 | (47) | 298 | (59) | 503 | (55) |
| 15-24 | 37 | (18) | 53 | (27) | 107 | (21) | 197 | (22) |
| ≥25 | 33 | (16) | 40 | (20) | 77 | (15) | 150 | (16) |
| Median, IQR | 10 | 6-19 | 14 | 9-22 | 12 | 9-18 | 15 | 8-19 |
| Year of diagnosis | | | | | | | | |
| 2013 | 9 | (4) | 13 | (7) | 56 | (11) | 78 | (9) |
| 2014 | 13 | (6) | 11 | (6) | 72 | (14) | 96 | (11) |
| 2015 | 18 | (9) | 28 | (14) | 77 | (15) | 123 | (13) |
| 2016 | 40 | (19) | 36 | (18) | 81 | (16) | 157 | (17) |

| 2017 | 38 | (18) | 52 | (27) | 87 | (17) | 177 | (19) |
|-------------------------------------|-----|------|-----|------|-----|------|-----|------|
| 2018 | 58 | (28) | 40 | (20) | 95 | (19) | 193 | (21) |
| 2019* | 32 | (15) | 16 | (8) | 41 | (8) | 89 | (10) |
| Adherence (%) | | | | | | | | |
| <50 | 16 | (7) | 22 | (11) | 52 | (10) | 90 | (10) |
| 50-79 | 47 | (23) | 57 | (29) | 120 | (24) | 224 | (24) |
| 80-99 | 47 | (23) | 55 | (28) | 164 | (32) | 266 | (29) |
| ≥100 | 36 | (17) | 36 | (19) | 109 | (21) | 181 | (20) |
| Unknown † | 62 | (30) | 26 | (13) | 64 | (13) | 152 | (17) |
| Clinical manifestatio | n ‡ | | | | | | | |
| Major | | | | | | | | |
| Carditis | 6 | (3) | 14 | (7) | 167 | (33) | 187 | (20) |
| Joint | 172 | (83) | 182 | (93) | 433 | (85) | 787 | (86) |
| Sydenham chorea | 3 | (1) | 0 | (0) | 62 | (12) | 65 | (7) |
| Skin | 2 | (1) | 1 | (1) | 7 | (1) | 10 | (1) |
| Minor | | | | | | | | |
| Fever | 51 | (24) | 60 | (31) | 340 | (67) | 451 | (49) |
| Elevated ESR or CRP | 12 | (14) | 9 | (6) | 11 | (2) | 32 | (5) |
| Prolonged P-R interval on ECG | 10 | (5) | 19 | (10) | 196 | (39) | 225 | (25) |
| Other | | | | | | | | |
| Elevated GAS serological titre | 183 | (88) | 168 | (86) | 480 | (94) | 831 | (91) |
| GAS cultured from throat swab | 5 | (2) | 7 | (4) | 18 | (4) | 30 | (3) |
| Not recorded | 6 | (3) | 1 | (1) | 0 | (0) | 7 | (1) |

ARF = acute rheumatic fever; GAS = group A beta haemolytic streptococcus; ESR =

erythrocyte sedimentation rate; CRP = C-reactive protein; ECG = electrocardiogram; CM =
 clinical manifestation

217 * Note: only 6 months of data

218 † Note: includes those where prophylaxis data is not recorded and where prophylaxis was
 219 prescribed for <6 months.

220 ‡ Note: cases may have more than one clinical manifestation, therefore the total does not221 add up to 100%

222 ¥ Note: Elevated GAS serological titre or GAS cultured from throat swab only

223

Joint pain was the most common major Jones criterion for all ARF diagnostic categories.

225 Evidence of streptococcal infection (considered essential) was missing in 2% of cases

classified as definite ARF, and in approximately 10% of possible and probable ARF cases.

227 There were 2 deaths during the study period. The proportion of those adhering to penicillin

secondary prophylaxis was similar for possible and probable ARF but higher for definite ARF

(Table 2): the proportion receiving ≥80% of scheduled BPG injections was 37% and 46%
among possible and probable cases respectively, compared with 56% among definite ARF
cases. However, the proportion of possible ARF cases with unknown adherence was double
that among probable ARF and definite ARF cases (Error! Reference source not found.).
Each year, the number of ARF diagnoses increased (Fig 1).



234

Fig 1: Number of ARF diagnoses among Indigenous Australians, Northern Territory,
 2013-2018. ARF indicates acute rheumatic fever.

237

The proportion that was uncertain increased from 22/78 (28%) in 2013 when these diagnostic categories started to be recorded, to 98/193 (51%) in 2018 (**Error! Reference source not**

240 found.).

241

242 Disease progression

After excluding cases with zero disease-free survival time, a total of 92 (13%) cases experienced disease progression during the study period. Of those with an initial diagnosis of definite ARF, 61/348 (18%) experienced disease progression, compared to 20/181 (11%) with probable ARF and 11/203 (5%) with possible ARF. Of those who progressed, 37/61 (61%)

with definite ARF, 10/20 (50%) with probable ARF, and 5/11 (45%) with possible ARF (total of
52/92 or 57%) were diagnosed with RHD during the study period. Overall, progression to RHD
was reported in 37/348 (11%) definite ARF, 10/181 (6%) probable ARF, and 5/203 (2%)
possible ARF.

251

252 Possible ARF had the best probability of survival free of disease progression and definite ARF

had the worst survival probability (*p*=0.0043; log rank test; Fig 2).

254



Fig 2: Kaplan-Meier progression-free survival estimates by initial ARF diagnosis among Indigenous Australians, Northern Territory, 2013-2019. ARF = acute rheumatic fever.

- 258
- 259 For possible and probable ARF, the risk of disease progression continued to increase each
- 260 year up to 4 years and 3 years since initial diagnosis respectively. For definite ARF, the risk
- of disease progression continued to increase each year of the follow-up period (Table 3).
- 262

Table 3: Cumulative incidence risk of disease progression by year of follow-up among Indigenous Australians, Northern Territory, 2013-2019

| naigene | | | | | | |
|---------|----------------------|----------------------|-----------------------|--|--|--|
| Year | Possible ARF | Probable ARF | Definite ARF | | | |
| | %, CI (95%) | %, CI (95%) | %, CI (95%) | | | |
| 1 | 2.46 (0.93 - 6.44) | 9.03 (5.54 – 14.55) | 8.66 (6.05 – 12.32) | | | |
| 2 | 4.85 (2.31 – 10.03) | 12.13 (7.87 – 18.45) | 14.43 (10.87 – 19.02) | | | |
| 3 | 9.05 (4.72 – 17.00) | 13.54 (8.78 – 20.59) | 17.98 (13.83 – 23.19) | | | |
| 4 | 11.44 (5.97 – 21.33) | 13.54 (8.78 – 20.59) | 22.19 (17.22 – 28.33) | | | |
| 5 | 11.44 (5.97 – 21.33) | 13.54 (8.78 – 20.59) | 23.26 (18.01 – 29.73) | | | |
| 5.5* | 11.44 (5.97 – 21.33) | 13.54 (8.78 – 20.59) | 33.55 (23.61 - 46.21) | | | |

265 266 *Only six months of data are available for the final year

267 Cox proportional hazards regression indicated that disease progression was 2.19 times more

268 likely in those with definite ARF than those with possible ARF (p=0.026) (Table 4).

| 269 | Table 4. Cox proportional h | azards analysis of predictors a | issociated with disease p | progression among | Indigenous Australians, |
|-----|-----------------------------|---------------------------------|---------------------------|-------------------|-------------------------|
|-----|-----------------------------|---------------------------------|---------------------------|-------------------|-------------------------|

270 Northern Territory, 2013-2019

| Variable | Hazard Ratio | Confidence Interval (95%) | P value |
|--|--------------|---------------------------|---------|
| ARF Diagnosis | | | |
| Possible ARF | Ref | | |
| Probable ARF | 1.44 | 0.66 – 3.15 | 0.353 |
| Definite ARF | 2.19 | 1.10 - 4.34 | 0.026 |
| Sex | | | |
| Male | Ref | | |
| Female | 1.06 | 0.67 – 1.67 | 0.811 |
| Age group (years) | | | |
| 0-4 | 0.73 | 0.26 - 2.06 | 0.552 |
| 5-14 | Ref | | |
| 15-24 | 1.28 | 0.75 – 2.20 | 0.366 |
| ≥25 | 1.71 | 0.93 – 3.15 | 0.084 |
| Adherence | | | |
| <50% | 0.31 | 0.09 – 1.11 | 0.072 |
| 50-79% | 1.48 | 0.66 – 3.29 | 0.337 |
| 80-99% | Ref | | |
| ≥100% | 2.22 | 0.86 - 5.78 | 0.100 |
| Clinical manifestations | | | |
| Carditis and/or chorea with or without joint manifestation | Ref | | |
| Joint manifestation only (i.e. no carditis, no chorea) | 0.48 | 0.24 – 0.95 | 0.035 |

271 ARF = acute rheumatic fever

272 Note:

1. Sample size for this analysis is 595 cases (137 cases missing drug adherence data and 181 cases with zero survival time were excluded)

274 2. Proportional hazard assumptions were not met for drug adherence nor joint manifestation and therefore, an interaction term with linear time $\frac{275}{1000}$ was fitted for these 2 factors (likelihood ratio test Chi2(2) = 14.0; Chi2(1) = 7.4. D<0.01 for both). The time was interaction term with linear time

was fitted for these 2 factors (likelihood ratio test Chi2(3) = 14.9; Chi2(1) = 7.4, P<0.01 for both). The time varying effect for joint manifestation was 1.7 (P=0.012) and 2.0 for prophylaxis adherence of <50% (P=0.010), both indicating a weakening protective effect with time.

277 The analysis also indicated that having joint manifestations only with no carditis nor chorea at 278 initial diagnosis of ARF was protective, with this group being 52% less likely to experience 279 disease progression compared with those who had other clinical manifestations including 280 carditis and/or chorea at initial diagnosis and with or without joint manifestation (p=0.035) 281 (Table 4). Disease progression was equally likely between sexes and age groups. In this 282 dataset, the association between penicillin adherence and progression was counterintuitive 283 and not statistically significant. People who had higher adherence were those who had disease 284 progression (Table 4).

285

286 Risk of developing rheumatic heart disease

287 The proportion of those who had no baseline carditis but still progressed to RHD is presented

by clinical manifestation (joint-only or chorea-only) in Table 5. Of those who progressed to

289 RHD with joint-only manifestations, 46% (17/37) progressed after one year. Of those who

progressed to RHD with chorea-only manifestations, only 3% (1/30) progressed after one year.

291 An additional case with neither chorea nor joint manifestations also progressed to RHD after

one year, bringing the total cases with progression to RHD after one year to be 19 cases.

293

294Table 5: Progression to RHD by clinical manifestation among Indigenous Australians,295Northern Territory, 2013-2019

| ARF | Joint-only with no baseline | | Chorea-only with no baseline | | |
|--------------------|-----------------------------|--------------------|------------------------------|--------------------|--|
| diagnosis | echocardiog | raphic pathology | echocardiographic pathology | | |
| | Total cases N | Progression to RHD | Total cases N | Progression to RHD | |
| | | n (%) | | n (%) | |
| Possible ARF | 167 | 4 (2%) | 2 | 0 (0%) | |
| Probable ARF | 164 | 10 (6%) | 0 | - | |
| Definite ARF | 229 | 23 (10%) | 28 | 3 (11%) | |
| All ARF / total | 560 | 37 (7%) | 30 | 3 (10%) | |

296 ARF = acute rheumatic fever

297 Note: 181 cases with zero survival time were excluded from this analysis

- 298 The multinomial logistic regression model demonstrated a significantly higher risk of
- 299 progression from no RHD to RHD if the initial diagnosis was definite compared to possible
- 300 ARF (p<0.001 for both mild and moderate-severe RHD outcomes) (Table 6).

301 Table 6: Multinomial logistic regression of initial ARF diagnosis and development of RHD, by RHD severity, among Indigenous 302 Australians, Northern Territory, 2013-2019

| Multinomial model | Relative Risk Ratio | Confidence Interval (95%) | P value | | | |
|--|--------------------------------|-------------------------------------|-------------|--|--|--|
| Risk to develop mild RHD compared to no RHD after an initial ARF diagnosis | | | | | | |
| ARF diagnosis | | | | | | |
| ARF possible | Ref | | | | | |
| ARF probable | 2.27 | 0.91-5.64 | 0.078 | | | |
| ARF definite | 6.39 | 2.85-14.35 | < 0.001 *** | | | |
| Age group | | | | | | |
| <= 4 yrs | 0.29 | 0.07-1.26 | 0.098 | | | |
| 5-14 yrs | Ref | | | | | |
| 15-24 yrs | 1.71 | 1.04-2.81 | 0.034 * | | | |
| >=25 yrs | 1.98 | 1.11-3.54 | 0.021 * | | | |
| Clinical Manifestations | | | | | | |
| Carditis only – Yes | 0.95 | 0.27-3.32 | 0.939 | | | |
| Joint only – Yes | 0.49 | 0.32-0.76 | 0.002 ** | | | |
| Adherence | | | | | | |
| <50% | 0.49 | 0.24-1.01 | 0.054 | | | |
| 50-79% | 0.77 | 0.47-1.26 | 0.294 | | | |
| 80-99% | Ref | | 0.591 | | | |
| ≥100% | 0.86 | 0.50-1.48 | | | | |
| Gender – Female | | | 0.084 | | | |
| Risk to develop r | noderate to severe RHD compare | d to no RHD after an initial ARF di | iagnosis | | | |
| ARF diagnosis | | | | | | |
| ARF possible | Ref | | | | | |
| ARF probable | 2.51 | 0.46-13.72 | 0.289 | | | |
| ARF definite | 13.92 | 3.22-60.16 | <0.001*** | | | |
| Age group | | | | | | |
| <= 4 yrs | 1.80 | 0.64-5.04 | 0.261 | | | |
| 5-14 yrs | Ref | | | | | |
| 15-24 yrs | 1.88 | 0.98-3.61 | 0.059 | | | |
| >=25 yrs | 2.11 | 0.94-4.72 | 0.071 | | | |
| Clinical Manifestations | | | | | | |

| Carditis only – Yes | 3.14 | 1.11-8.82 | 0.030* |
|---------------------|------|-----------|-----------|
| Joint only – Yes | 0.19 | 0.11-0.34 | <0.001*** |
| Drug adherence | | | |
| <50% | 0.20 | 0.06-0.74 | 0.015* |
| 50-79% | 0.67 | 0.34-1.31 | 0.237 |
| 80-99% | Ref | | |
| ≥100% | 1.41 | 0.75-2.66 | 0.281 |
| Gender – Female | 0.90 | 0.52-1.55 | 0.710 |

ARF = acute rheumatic fever; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; ECG = electrocardiograph; GAS = Group A Streptococcus; *** P<0.001; ** P<0.010; * P<0.050 Note: sample size for this analysis is 761 cases (151 cases missing drug adherence data were excluded)

There was a strong protective effect for those with joint manifestations only, with a 51% reduced risk to progress to mild RHD and an 81% reduced risk to progress to moderate or severe RHD from no RHD, with all other covariates held constant (p<0.001 for both; Table 6). There was a three-fold increased risk of developing moderate-severe RHD compared to no RHD for patients with carditis-only clinical manifestation (p=0.030).

311

312 Penicillin adherence

The GLMM estimated that patients with definite ARF had a significantly higher adherence to antibiotic prophylaxis compared with probable ARF (p=0.024). Possible ARF, requiring only 12 months of treatment, was excluded from adherence comparisons. Time on prophylaxis was also significantly inversely associated with adherence, with adherence being higher in the first year after diagnosis and falling in years 2 to 6 after ARF diagnosis, for both definite and probable ARF (p<0.001 for all) (Fig 3).

319



Fig 3: Drug adherence by initial ARF diagnosis and year since diagnosis among
 Indigenous Australians, Northern Territory, 2013-2019.
 ARF = acute rheumatic fever.

325 **Discussion**

326 To our knowledge, this is the first time that outcomes of possible and probable ARF have been 327 determined. We show that since introduction of these diagnostic categories, they now make 328 up over 40% of all initial ARF diagnoses in the Australian jurisdiction with the highest ARF 329 burden. The diagnostic categories appear to be well applied by clinicians: the vast majority of 330 children and young people diagnosed with possible ARF (95%) and probable ARF (89%) did 331 not progress to definite ARF or RHD. These data are reassuring both for clinicians about the 332 appropriate application of these diagnostic categories, and for patients and their families about 333 the likelihood of a good outcome. However, the fact that some patients do progress 334 emphasises that the Revised Jones criteria can still be inadequately sensitive in a high-burden 335 environment, and the categories of 'possible' and 'probable' ARF add value by capturing some 336 true cases who require institution of secondary prevention and appropriate clinical follow up.

337

338 Our findings highlight that definite, probable and possible ARF represent three distinct 339 diagnostic categories with different prognoses. In a high-incidence setting, including the category of 'possible' ARF captures an important patient group who might otherwise receive 340 341 an alternative generic diagnosis such as 'viral illness' or 'musculoskeletal pain'. International 342 guidelines currently only articulate two categories: definite and probable ARF.(6) While many 343 people labelled with possible ARF in our dataset may never have had true ARF, is not entirely 344 benign: 4/200 (2%) with an initial diagnosis of possible ARF and a normal echocardiogram 345 developed RHD; 3 within 12 months (1.5%), and 1 within 24 months (0.5%). The inability to 346 predict which individuals are the ones most likely to progress highlights the need for 347 biomarkers to diagnose and risk-stratify ARF. More research in this domain is needed.(13) 348 Current Australian guidelines recommend 12 months of secondary prophylaxis after a 349 diagnosis of possible ARF.(3) Our findings support this approach, since development of RHD 350 more than 12 months after 'possible ARF' appears to be no more common than the

background population RHD risk, based on RHD population prevalence of 2% in 5-9 year old
children undergoing echocardiographic screening, and 6.8% in 10-15 year olds, in a highburden NT setting.(14)

354

Healthcare providers appear to be increasingly confident in accurately applying 'probable' and 'possible' ARF diagnoses since 2013 when these were defined and introduced into the NT register. When total ARF diagnoses are captured, our data show that the increases over time chiefly represent improving detection of uncertain cases from 22/78 (28%) in 2013 to 98/193 (51%) in 2018, with a smaller proportional increase in numbers of definite ARF (Fig 1). Efforts to improve detection have included promotion of accessible clinical practice guidelines (2, 3, 15) and a diagnosis calculator available for smartphone use.(16)

362

363 The clinical manifestations of ARF we report are supported by previous NT data, (17) showing 364 arthritis to be most common major criterion followed by carditis then chorea, with almost all 365 additionally having fever. (18) Rheumatic carditis detected on echocardiogram is diagnostic of 366 definite ARF and should not be classified as possible or probable ARF. Possible and probable 367 cases noted to have echocardiographic valvar disease may have had known RHD and 368 presented with an acute illness not meeting criteria for definite ARF. When a child with RHD 369 presents with fever or elevated inflammatory markers, distinguishing ARF from other febrile 370 conditions with underlying RHD can be difficult and may result in a 'possible' or 'probable' ARF 371 diagnosis; the child is already prescribed penicillin prophylaxis but a new ARF diagnosis may 372 alter the duration of prophylaxis depending on their age. Sydenham chorea is synonymous 373 with ARF; once alternative causes of chorea have been excluded, a child with chorea 374 (especially if from a high-risk setting such as the NT) receives a diagnosis of definite ARF. 375 The possible and probable cases in this study noted to have chorea may, for instance, have 376 had a transient movement disorder not clearly evident as Sydenham chorea. Definite ARF 377 diagnoses require demonstration of recent streptococcal infection, except for when Sydenham

378 chorea is present, the onset of which might be very delayed.(3) The small number of definite 379 cases who lacked evidence of streptococcal infection on serology or throat swab may have 380 had chorea, may have had serological tests too early in disease without opportunity for 381 convalescent serology to be done, or the clinician may have chosen to override the 382 recommended diagnostic criteria.

383

384 The cumulative incidence risk of disease progression per year for those diagnosed with 385 possible ARF stopped increasing at 11%, 4 years from initial diagnosis, and for those 386 diagnosed with probable ARF at 14%, 3 years from initial diagnosis. In contrast, the cumulative 387 incidence risk of disease progression after definite ARF continued to increase each year since 388 initial diagnosis, from 9% at 1 year to 34% at 5.5 years from initial diagnosis (Table 3). While 389 the trend of increasing risk of disease progression from initial diagnosis largely concurs with 390 previous studies, the cumulative incidence risk of progression to RHD after definite ARF was 391 lower in our study. For example, a study of 1997-2013 Northern Territory data found that the 392 cumulative risk of progression from definite ARF to RHD increased from 27% at 1 year from 393 initial diagnosis to 52% at 10 years since initial diagnosis,(9) and another study of 1997-2010 394 data reported that the risk of progression from definite ARF to RHD was 35% at 1 year and 395 61% at 10 years.(19) The lower rate of disease progression in our study may reflect exclusion 396 of the most-severe ARF cases from cumulative incidence calculations, since they already had 397 the outcome of interest (RHD) at baseline. Other explanations may include improving delivery 398 of secondary prophylaxis which occurred during our study period(20), or greater clinical 399 detection over time of more subtle ARF cases which are less likely to progress, which the 400 increasing ARF detection rates reported here suggest.

401

402 Cox proportional hazards analysis demonstrated that those with more certain ARF were more 403 likely to experience disease progression (compared to those with possible ARF). The risk of 404 progression from no RHD to RHD was significantly higher if the initial diagnosis was definite

405 ARF compared to possible ARF (p<0.001 for both mild and moderate-severe RHD outcomes) 406 (Table 6). Those who had only joint manifestations at initial diagnosis of ARF were 52% less 407 likely to experience disease progression (compared to carditis and/or chorea). Joint-only 408 manifestations, which may only fulfill criteria for possible or probable ARF, may in other 409 settings be labelled as 'post streptococcal reactive arthritis', considered to be a separate entity 410 from ARF.(21, 22) However, since 6.6% (37/560) of people still developed RHD in our series 411 after initial joint-only presentations, we consider a diagnosis of ARF and provision of 412 secondary prophylaxis to be safer in our context.

413

414 In this dataset, people with ARF who had greater penicillin adherence were also those with a 415 higher risk of disease progression - but this association was not statistically significant (Table 416 4). Furthermore, of the cases that progressed (and had adherence data), less than half (40/86; 417 47%) were adherent to \geq 80% of their BPG injections and adherence for both definite and 418 probable ARF cases was shown to decline over time from initial diagnosis (Figure 3). These 419 findings may be attributable to the association between disease severity and adherence. 420 Previous research using the same NT register, but an earlier time period, identified that those 421 with most severe disease (e.g. requiring surgery) were those who were subsequently most 422 adherent, potentially attributable to higher-level health system supports implemented for these 423 high-risk individuals, and greater patient understanding of the risks of non-adherence. (10) 424 The same paper showed a clear protective effect of adherence on ARF outcomes when 425 adherence prior to the event of interest was examined. Therefore, we conclude that adherence 426 reduces ARF recurrences or RDH progression, but in this dataset, we were unable to 427 demonstrate this relationship. Also, we used percent adherence which does not necessarily 428 factor in 'days at risk'(10); that is, the timing of dose administration (e.g. 13 BPG doses may 429 be given in a 12 month period, but if there are gaps of greater than 28 days, then the patient 430 will be at risk of ARF recurrence during those times).

432 Strengths of this study include that it is the first to include outcomes for possible and probable 433 ARF cases and that ARF is notifiable in the NT and therefore ARF diagnoses are well captured 434 and documented in the NT RHD Register. A limitation of this study is that a longer period of 435 follow-up time may have captured more events. For example, disease progression from ARF 436 to RHD is known to still occur at 10 years from initial diagnosis.(19) However, for possible and 437 probable ARF, the risk of disease progression appeared to stabilise approximately 4 years 438 from initial diagnosis (within the 5.5-year study timeframe). Another limitation is missed 439 diagnoses of ARF; up to 75% of newly diagnosed cases of RHD in northern Australia have 440 not been previously diagnosed with ARF.(3, 23) As noted, concurrent ARF and RHD 441 diagnoses were excluded since they had a disease-free survival time of zero so could not be 442 included in analysis of progression. Exclusion of these most severe ARF cases impacted 443 sample size and statistical rigour, follow-up time and the ability to calculate median survival 444 time, an important factor in the interpretation of survival data.(24)

445

446 **Conclusion**

This study provides much needed data about the likelihood of disease progression for children 447 448 and young people given a diagnosis of possible and probable ARF. Children and their families 449 can be reassured that possible ARF, probable ARF and ARF affecting the joints only, carry 450 relatively good prognoses. These diagnoses are more consistent with post-streptococcal 451 reactive arthritis than true ARF. However, secondary prophylaxis with penicillin is still of critical 452 importance given the morbidity of recurrences and the small but present risk of progression to 453 RHD. The data provide good news that clinicians appear to be detecting and reporting more cases of uncertain ARF over time, a critical step in avoiding missed opportunities for 454 455 prevention.

457 Acknowledgements

- 458 This project was undertaken as part of the Master of Public Health at the University of
- 459 Melbourne. The authors would like to thank Dr Jessica de Dassel, RHD Registry Data Analyst,
- 460 and Dr Vicki Krause, Northern Territory Centre for Disease Control Director, for facilitating the
- 461 data request and approval.
- 462

463 **References**

- Katzenellenbogen, J. M., Bond-Smith D., Seth R. J., Dempsey K., Cannon J., Stacey
 I., et al. Contemporary Incidence and Prevalence of Rheumatic Fever and Rheumatic
 Heart Disease in Australia Using Linked Data: The Case for Policy Change. Journal of
 the American Heart Association. 2020;9(19):e016851.
- Ralph, A. P., Currie B. J., Noonan S., Wade V. The 2020 Australian guideline for
 prevention, diagnosis and management of acute rheumatic fever and rheumatic heart
 disease. Medical Journal of Australia. 2021;214(5):220-227.
- 471 3. RHDAustralia (ARF/RHD writing group). The 2020 Australian guideline for
 472 prevention, diagnosis and management of acute rheumatic fever and rheumatic
 473 heart disease (3rd edition). Australia2020.
- 474 4. Dajani, A. S., Ayoub E., Bierman F. Z., Bisno A. L., Denny F. W., Durack D. T., et al.
 475 Guidelines for the diagnosis of rheumatic fever: Jones Criteria, 1992 update. Journal of 476 the American Medical Association. 1992;268(15):2069-2073.
- 477 5. WHO Study Group on Rheumatic Fever and Rheumatic Heart Disease. Rheumatic
 478 fever and rheumatic heart disease: report of a WHO expert consultation, Geneva, 20
 479 October 1 November 2001. Geneva, Switzerland: World Health Organization; 2004.
- Gewitz, M. H., Baltimore R. S., Tani L. Y., Sable C. A., Shulman S. T., Carapetis J., et
 al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era
 of Doppler echocardiography: a scientific statement from the American Heart
 Association. Circulation. 2015;131(20):1806-1818.
- Ralph, A., Jacups S., McGough K., McDonald M., Currie B. J. The Challenge of Acute
 Rheumatic Fever Diagnosis in a High-Incidence Population: A Prospective Study and
 Proposed Guidelines for Diagnosis in Australia's Northern Territory. Heart, Lung and
 Circulation. 2006;15(2):113-118.
- 488
 488
 489
 489
 480
 480
 480
 481
 481
 481
 482
 483
 484
 484
 484
 485
 485
 486
 486
 486
 487
 487
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
- 491 9. He, V. Y. F., Condon J. R., Ralph A. P., Zhao Y., Roberts K., de Dassel J. L., et al.
 492 Long-term outcomes from acute rheumatic fever and rheumatic heart disease a data493 linkage and survival analysis approach. Circulation. 2016;134(3):222-232.
- de Dassel, J. L., de Klerk N., Carapetis J. R., Ralph A. P. How Many Doses Make a
 Difference? An Analysis of Secondary Prevention of Rheumatic Fever and Rheumatic
 Heart Disease. Journal of the American Heart Association. 2018;7(24):1-22.
- 497 11. Australia Bureau of Statistics. Australian demographic statistics Canberra, Australia: 498 Australia Bureau of Statistics; 2018 [Available from: 499 <u>https://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/5E432E26B9EB0D28CA25</u> 500 <u>841E00129B45/\$File/31010_dec%202018.pdf</u>.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.01.23285323; this version posted February 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Australian Bureau of Statistics. Estimated resident Aboriginal and Torres Strait
Islander and Non-Indigenous population, States and Territories, Remoteness Areas 30 June 2016 Canberra, Australia: Australian Bureau of Statistics; 2016 [Available
from:
<u>https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3238.0.55.001June%2020</u>
16?OpenDocument.

- Ralph, A. P., Yan J., Remenyi B., Mayo M., Webb R., Wilson N., et al. Searching for a technology-driven acute rheumatic fever test: The START study protocol. BMJ Open.
 2021;11(9):e053720.
- Francis, J. R., Fairhurst H., Hardefeldt H., Brown S., Ryan C., Brown K., et al.
 Hyperendemic rheumatic heart disease in a remote Australian town identified by echocardiographic screening. Medical Journal of Australia. 2020;213(3):118-123.
- 513 15. Ralph, A. P., Currie B. J. Therapeutics for rheumatic fever and rheumatic heart 514 disease. Australian Prescriber. 2022;45(4):104-112.
- 515 16. Fisher, E., Currie B. J., Ralph A. P., James C., Mosca D. Evaluation of an ARF
 516 diagnosis calculator: a survey and content analysis. BMC Medical Informatics and
 517 Decision Making. 2022;22(1):77-88.
- Jack, S., Moreland N. J., Meagher J., Fittock M., Galloway Y., Ralph A. P.
 Streptococcal Serology in Acute Rheumatic Fever Patients: Findings From 2 Highincome, High-burden Settings. The Pediatric Infectious Disease Journal. 2019;38(1):16.
- 522 18. Carapetis, J. R., Beaton A., Cunningham M. W., Guilherme L., Karthikeyan C., Mayosi
 523 B. M., et al. Acute rheumatic fever and rheumatic heart disease. Nature Reviews.
 524 2016;2:1-24.
- Lawrence, J. G., Carapetis J. R., Griffiths K., Edwards K., Condon J. R. Acute
 rheumatic fever and rheumatic heart disease incidence and progression in the
 Northern Territory of Australia, 1997 to 2010. Circulation. 2013;128(5):492-501.
- Ralph, A. P., Read C., Johnston V., de Dassel J. L., Bycroft K., Mitchell A., et al.
 Improving delivery of secondary prophylaxis for rheumatic heart disease in remote
 Indigenous communities: study protocol for a stepped-wedge randomised trial. Trials.
 2016;17(1):51-63.
- 532 21. van der Helm-van Mil, A. H. M. Acute rheumatic fever and poststreptococcal reactive 533 arthritis reconsidered. Current Opinion in Rheumatology. 2010;22(4):437-442.
- Barash, J., Mashiach E., Navon-Elkan P., Berkun Y., Harel L., Tauber T., et al.
 Differentiation of post-streptococcal reactive arthritis from acute rheumatic fever.
 Journal of Pediatrics. 2008;153(5):696-699.
- 537 23. Hardie, K., de Dassel J. L., Ralph A. P. RHD elimination: action needed beyond
 538 secondary prophylaxis. Australian and New Zealand Journal of Public Health.
 539 2020;44(5):427.
- 540 24. Betensky, R. A. Measures of follow-up in time-to-event studies: Why provide them and what should they be? Clinical Trials. 2015;12(4):403-408.